A092040 Stock Overview
Operates as an industrial biotechnology company in South Korea and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Amicogen, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩4,100.00 |
| 52 Week High | ₩9,400.00 |
| 52 Week Low | ₩3,075.00 |
| Beta | 1.06 |
| 1 Month Change | 13.73% |
| 3 Month Change | -6.50% |
| 1 Year Change | -34.19% |
| 3 Year Change | -71.77% |
| 5 Year Change | -66.19% |
| Change since IPO | -42.96% |
Recent News & Updates
Recent updates
Amicogen, Inc. (KOSDAQ:092040) Held Back By Insufficient Growth Even After Shares Climb 35%
Jan 08
Revenues Working Against Amicogen, Inc.'s (KOSDAQ:092040) Share Price
Nov 11Little Excitement Around Amicogen, Inc.'s (KOSDAQ:092040) Revenues As Shares Take 27% Pounding
Jun 27Does Amicogen (KOSDAQ:092040) Have A Healthy Balance Sheet?
Jun 19Amicogen, Inc. (KOSDAQ:092040) Held Back By Insufficient Growth Even After Shares Climb 39%
Mar 21With EPS Growth And More, Amicogen (KOSDAQ:092040) Is Interesting
Mar 23Should Amicogen (KOSDAQ:092040) Be Disappointed With Their 24% Profit?
Mar 05Is Amicogen (KOSDAQ:092040) A Risky Investment?
Feb 15
What Kind Of Investors Own Most Of Amicogen, Inc. (KOSDAQ:092040)?
Jan 31Could The Market Be Wrong About Amicogen, Inc. (KOSDAQ:092040) Given Its Attractive Financial Prospects?
Jan 14Amicogen (KOSDAQ:092040) Is Growing Earnings But Are They A Good Guide?
Dec 30Is Now The Time To Put Amicogen (KOSDAQ:092040) On Your Watchlist?
Dec 15Did You Miss Amicogen's (KOSDAQ:092040) 37% Share Price Gain?
Nov 30Shareholder Returns
| A092040 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -7.6% | -2.7% | 0.3% |
| 1Y | -34.2% | 24.8% | -1.5% |
Return vs Industry: A092040 underperformed the KR Biotechs industry which returned 24.8% over the past year.
Return vs Market: A092040 underperformed the KR Market which returned -1.5% over the past year.
Price Volatility
| A092040 volatility | |
|---|---|
| A092040 Average Weekly Movement | 9.6% |
| Biotechs Industry Average Movement | 8.9% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in KR Market | 12.8% |
| 10% least volatile stocks in KR Market | 3.4% |
Stable Share Price: A092040's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A092040's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | n/a | Piao Zhe | www.amicogen.com |
Amicogen, Inc. operates as an industrial biotechnology company in South Korea and internationally. The company develops, produces, and sells of enzymes and new materials; and produces food-related additives and health functional food. It manufactures and sells of biopharmaceutical materials and resins for purifying pharmaceutical proteins and health and beauty products.
Amicogen, Inc. Fundamentals Summary
| A092040 fundamental statistics | |
|---|---|
| Market cap | ₩224.75b |
| Earnings (TTM) | -₩35.70b |
| Revenue (TTM) | ₩155.74b |
1.4x
P/S Ratio-6.3x
P/E RatioIs A092040 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A092040 income statement (TTM) | |
|---|---|
| Revenue | ₩155.74b |
| Cost of Revenue | ₩106.08b |
| Gross Profit | ₩49.66b |
| Other Expenses | ₩85.36b |
| Earnings | -₩35.70b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -651.30 |
| Gross Margin | 31.89% |
| Net Profit Margin | -22.92% |
| Debt/Equity Ratio | 78.4% |
How did A092040 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/19 17:45 |
| End of Day Share Price | 2025/01/17 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Amicogen, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mujinn Lee | Cape Investment & Securities Co., Ltd. |
| So-Eun Choi | LS Securities Co., Ltd. |